12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kalydeco ivacaftor regulatory update

FDA approved Kalydeco ivacaftor to treat cystic fibrosis in patients aged 6 and older who have at least 1 copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. FDA said Kalydeco is the first drug approved that targets the defective...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >